Skip to content

Study · Randomized controlled trial · n = 291 · 2023

9 results

Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.

Wang W, Yan X, Cheng Z, Zhang Q, Wang R, Deng Y, Ma J, Zhu D

Diabetes, obesity & metabolism21 Sept 2023Cited by 7 (Europe PMC)

PMID37732487 (opens in a new tab)DOI10.1111/dom.15263 (opens in a new tab)PepBankPUB-37732487
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Chinese patients with type 2 diabetes, dulaglutide added to glargine reduced HbA1c more than placebo added to glargine.

    In plain wordsIn patients with diabetes, dulaglutide reduced HbA1c more than placebo with the same insulin treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n = 291

    Comparator
    Placebo with insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2%
    dulaglutide/glargine
    HbA1c change
    −1.1%
    placebo/glargine
    HbA1c change difference
    −1%
    dulaglutide/glargine vs placebo/glargine, 95% CI -1.1 to -0.8

    Source sentences

    Summary
    The least squares (LS) mean ± standard error change in HbA1c from baseline to Week 28 was -2.0 ± 0.08% with dulaglutide/glargine and -1.1 ± 0.07% with placebo/glargine (LS mean difference: -1.0%, 95% confidence interval [CI] -1.1 to -0.8; P < 0.001)
    2 context sentences
    Summary · context
    The primary endpoint was the superiority of dulaglutide/glargine to placebo/glargine for change from baseline in HbA1c at Week 28.
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Chinese patients with type 2 diabetes, more dulaglutide/glargine recipients achieved HbA1c below 7.0% than placebo/glargine recipients.

    In plain wordsIn patients with diabetes, more people reached the HbA1c target with dulaglutide than placebo alongside insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c below target
    Study

    n = 291

    Comparator
    Placebo with insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Responders
    75.9%
    dulaglutide/glargine
    Responders
    33.8%
    placebo/glargine

    Source sentences

    Summary
    more patients receiving dulaglutide/glargine achieved HbA1c levels <7.0% (75.9% vs. 33.8%; P < 0.001 vs. placebo/glargine).
    1 context sentence
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Chinese patients with type 2 diabetes, weight decreased with dulaglutide/glargine and increased with placebo/glargine.

    In plain wordsIn patients with diabetes, weight fell with dulaglutide plus insulin and rose with placebo plus insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    n = 291

    Comparator
    Placebo with insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Weight difference
    −1.2 kg
    versus placebo/glargine

    Source sentences

    Summary
    Body weight decreased with dulaglutide/glargine and increased with placebo/glargine (LS mean difference: -1.2 kg, 95% CI -1.8 to - 0.6; P < 0.001).
    1 context sentence
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Chinese patients with type 2 diabetes, dulaglutide/glargine reduced fasting serum glucose more than placebo/glargine.

    In plain wordsIn patients with diabetes, dulaglutide plus insulin lowered fasting glucose more than placebo plus insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting serum glucose
    Study

    n = 291

    Comparator
    Placebo with insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Glucose difference
    −0.8 mmol/L
    versus placebo/glargine

    Source sentences

    Summary
    Reductions in fasting serum glucose were greater with dulaglutide/glargine than with placebo/glargine (LS mean difference: -0.8 mmol/L, 95% CI -1.1 to - 0.5; P < 0.001).
    1 context sentence
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.
  5. 05HumanRandomized controlled trialSafety outcome

    In Chinese patients with type 2 diabetes, hypoglycaemia incidence was similar with dulaglutide/glargine and placebo/glargine.

    In plain wordsIn patients with diabetes, low blood sugar occurred at similar rates with dulaglutide or placebo alongside insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHypoglycaemia incidence
    Study

    n = 291

    Comparator
    Placebo with insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Hypoglycaemia
    29.2%
    dulaglutide/glargine
    Hypoglycaemia
    31.3%
    placebo/glargine

    Source sentences

    Summary
    The incidence of hypoglycaemia was similar with dulaglutide/glargine and placebo/glargine (29.2% vs. 31.3%; P = 0.704); no patient in either group had severe hypoglycaemia.
    1 context sentence
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.
  6. 06HumanRandomized controlled trialSafety outcome

    In Chinese patients with type 2 diabetes, neither dulaglutide/glargine nor placebo/glargine recipients had severe hypoglycaemia.

    In plain wordsIn patients with diabetes, neither treatment group had severe low blood sugar.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSevere hypoglycaemia
    Study

    n = 291

    Comparator
    Placebo with insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    The incidence of hypoglycaemia was similar with dulaglutide/glargine and placebo/glargine (29.2% vs. 31.3%; P = 0.704); no patient in either group had severe hypoglycaemia.
    1 context sentence
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.
  7. 07HumanRandomized controlled trialSafety outcome

    In Chinese patients with type 2 diabetes, decreased appetite occurred in 22.2% receiving dulaglutide/glargine.

    In plain wordsIn patients with diabetes, decreased appetite occurred in 22.2% receiving dulaglutide with insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDecreased appetite
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Decreased appetite
    22.2%
    dulaglutide/glargine

    Source sentences

    Summary
    The most common treatment-emergent adverse events with dulaglutide/glargine were decreased appetite (22.2%), diarrhoea (13.2%) and nausea (10.4%).
    1 context sentence
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.
  8. 08HumanRandomized controlled trialSafety outcome

    In Chinese patients with type 2 diabetes, diarrhoea occurred in 13.2% receiving dulaglutide/glargine.

    In plain wordsIn patients with diabetes, diarrhoea occurred in 13.2% receiving dulaglutide with insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDiarrhoea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Diarrhoea
    13.2%
    dulaglutide/glargine

    Source sentences

    Summary
    The most common treatment-emergent adverse events with dulaglutide/glargine were decreased appetite (22.2%), diarrhoea (13.2%) and nausea (10.4%).
    1 context sentence
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.
  9. 09HumanRandomized controlled trialSafety outcome

    In Chinese patients with type 2 diabetes, nausea occurred in 10.4% receiving dulaglutide/glargine.

    In plain wordsIn patients with diabetes, nausea occurred in 10.4% receiving dulaglutide with insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Nausea
    10.4%
    dulaglutide/glargine

    Source sentences

    Summary
    The most common treatment-emergent adverse events with dulaglutide/glargine were decreased appetite (22.2%), diarrhoea (13.2%) and nausea (10.4%).
    1 context sentence
    Summary · context
    In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1.5 mg once weekly or placebo once weekly.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.